New Leukemia Drug Shows Stunning First-Line Results, but Experts Urge Caution on Treatment Order

Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine regulatory and clinical crossroads. In December 2025, two phase III trials, BRUIN CLL-313 and BRUIN CLL-314, were published back to back and delivered results that many hematologists had been waiting years to see. Pirtobrutinib, a noncovalent inhibitor of Bruton tyrosine kinase (BTK), reduced the risk of progression or death by 80 percent compared with bendamustine plus rituximab in previously untreated patients, with a hazard ratio of 0.199 and a 24-month progression-free survival of 93.4 percent. In a separate head-to-head trial against ibrutinib, the long-standing covalent standard of care, pirtobrutinib proved non-inferior for efficacy while producing roughly one-sixth the incidence of atrial fibrillation, 2.4 percent versus 13.5 percent, and showed a strong progression-free survival signal in the treatment-naive subgroup with a hazard ratio of 0.24.

Regulators have moved quickly. After a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June 2026, the European Commission approved pirtobrutinib in August 2026 for adults with CLL across all lines of therapy, and an equivalent decision from the US Food and Drug Administration is anticipated in the second half of 2026. An accompanying editorial by Davids argued that the two trials open the door for noncovalent BTK inhibition as initial therapy. On the surface, the case seems overwhelming: a drug that works at least as well as the incumbent, with dramatically better cardiovascular tolerability, seems destined to become the new default first choice.

But a correspondence published in Annals of Hematology by Boyi Chen and Shenxian Qian throws a careful, technically grounded brake on that enthusiasm. The authors highlight what they call a sequencing asymmetry, a structural imbalance in the evidence that neither of the new trials was designed to address. The order in which the two BTK inhibitor classes are given, they argue, matters enormously, and only one of the two possible orders is currently supported by randomized evidence. That order is the covalent-first sequence, and the argument for preserving it rests on the molecular biology of drug resistance as much as on clinical trial data.

The covalent BTK inhibitors, including ibrutinib, acalabrutinib and zanubrutinib, bind permanently to a cysteine residue at position 481 of the BTK kinase. Resistance to these drugs most often emerges through the C481S mutation, which replaces that cysteine with serine and blocks covalent attachment while leaving the binding pocket otherwise intact. Crucially, pirtobrutinib does not depend on covalent chemistry, so it retains activity against C481-mutant BTK. In the phase 1/2 BRUIN study, pirtobrutinib achieved a 73.3 percent response rate and a median progression-free survival of 19.6 months in patients whose disease had progressed on a covalent inhibitor, regardless of C481 status. In the phase III BRUIN CLL-321 trial, it outperformed idelalisib plus rituximab or bendamustine plus rituximab in this setting, with a hazard ratio of 0.54 and a median progression-free survival of 14.0 versus 8.7 months. A patient who begins treatment with a covalent inhibitor therefore keeps a rational, evidence-backed exit ramp if resistance develops.

The reverse sequence has no comparable data, and the resistance mechanisms give concrete reason for concern. Work by Wang and colleagues showed that acquired resistance to pirtobrutinib does not arise through C481 but through a distinct set of kinase-domain mutations: V416L, A428D, M437R, T474I and L528W. Of these, A428D and L528W conferred in vitro cross-resistance to ibrutinib and prevented multiple covalent BTK inhibitors from inhibiting the mutant enzyme. In other words, a patient who progresses on first-line pirtobrutinib may harbor leukemic clones that have compromised not just one drug but much of the covalent class, the very class that currently anchors relapse management. Notably, no patient in the Wang series acquired a new C481 mutation on pirtobrutinib, indicating that the two drug classes select largely distinct mutations, and that the mutations selected by the noncovalent agent can reduce sensitivity to covalent drugs. As Mato and colleagues observed in the original BRUIN publication, no information is currently available on the efficacy of covalent BTK inhibitors in patients who receive pirtobrutinib first and in whom resistance develops.

Davids offers a reasonable counterargument: many older patients with comorbidities may need only one or two lines of therapy over their remaining lifetime, making downstream resistance a less salient concern. For that subgroup, Chen and Qian concur that first-line pirtobrutinib is defensible, since a single effective line may be the realistic horizon. But CLL is not uniformly a disease of the very old. Younger patients, and those with unmutated IGHV genes or TP53 aberrations, can expect disease courses lasting ten to twenty years and multiple lines of treatment. Patients with del(17p) were even excluded from the CLL-313 trial. For these individuals, sequencing is not a footnote but the central strategic question, and spending the noncovalent agent first may forfeit options decades before they are needed.

Nor does toxicity, the argument that once favored abandoning covalent inhibitors altogether, justify skipping the class today. The cardiovascular case against ibrutinib has been substantially overtaken by the second-generation covalent agents. Zanubrutinib more than halved the rate of atrial fibrillation compared with ibrutinib in the ALPINE trial, 5.2 percent versus 13.3 percent, while improving progression-free survival, and acalabrutinib reduced atrial fibrillation in the ELEVATE-RR trial, 9.4 percent versus 16.0 percent, with non-inferior efficacy. The covalent-first strategy also preserves later options: beyond pirtobrutinib monotherapy after covalent inhibitor failure, the triplet of pirtobrutinib with venetoclax and rituximab has outperformed venetoclax plus rituximab in previously treated disease in BRUIN CLL-322, with a hazard ratio of 0.547. Frontline pirtobrutinib, by contrast, forgoes at present the only BTK-inhibitor class with phase III-validated salvage value.

The authors are careful to qualify their own argument. The cross-resistance evidence is preclinical, resting on in vitro potency and binding studies, and every patient in the Wang series who developed a non-C481 mutation had prior exposure to ibrutinib, so whether frontline pirtobrutinib selects the same mutational spectrum is unknown. Cross-resistance is also not strictly one-directional, since mutations such as L528W have been reported, less frequently, after covalent inhibitor therapy as well. These uncertainties, the authors stress, argue for caution and surveillance rather than regulatory delay. They also caution against treating BTK degraders, an emerging class of drugs that eliminate BTK rather than merely blocking it, as a ready safety net. Degraders such as NX-2127 can degrade kinase-impaired mutants including L528W, and early-phase studies of BGB-16673 and bexobrutideg report rapid, durable responses, but the evidence remains at the abstract level, pivotal trials are still accruing patients, and A428D can itself confer resistance to degrader therapy.

From this analysis flow four concrete recommendations. First, frontline trials of noncovalent BTK inhibitors should mandate BTK and PLCG2 mutation testing at progression, so the field learns which mutations first-line pirtobrutinib actually selects in previously untreated patients. Second, real-world registries should systematically track responses to covalent agents after pirtobrutinib failure, which the authors identify as the single most urgent evidence gap. Third, routine practice should incorporate BTK and PLCG2 testing whenever a patient progresses on any BTK inhibitor, since the mutational profile at relapse directly informs what can work next. Fourth, forthcoming guideline updates should explicitly address sequencing, and post-pirtobrutinib outcomes should be collected systematically while reverse-sequence data remain absent.

The BRUIN program has undeniably given CLL a highly effective drug, and its first-line efficacy is not in doubt. What remains unknown is what early use may cost at relapse. Until prospective sequencing data emerge, the authors conclude, the uncertainty argues for an individualized, sequencing-aware choice rather than a wholesale shift of the treatment default, particularly for the younger patients whose long disease courses give the order of therapy its greatest weight.

Subject of Research: Treatment sequencing and resistance mechanisms for first-line pirtobrutinib in chronic lymphocytic leukemia

Article Title: Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia

Article References: Chen, B., & Qian, S. (2026). Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. Annals of Hematology, 105(9), Article 404. https://doi.org/10.1007/s00277-026-07264-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07264-x

Keywords: chronic lymphocytic leukemia, pirtobrutinib, BTK inhibitor, drug resistance, treatment sequencing, BTK C481S, kinase-domain mutations, BRUIN trials, cross-resistance, BTK degraders, hematology, clinical trials